184 related articles for article (PubMed ID: 20017885)
1. PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Frizzell KM; Kraus WL
Breast Cancer Res; 2009; 11(6):111. PubMed ID: 20017885
[TBL] [Abstract][Full Text] [Related]
2. A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors.
Inbar-Rozensal D; Castiel A; Visochek L; Castel D; Dantzer F; Izraeli S; Cohen-Armon M
Breast Cancer Res; 2009; 11(6):R78. PubMed ID: 19891779
[TBL] [Abstract][Full Text] [Related]
3. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
[TBL] [Abstract][Full Text] [Related]
4. The clinical development of inhibitors of poly(ADP-ribose) polymerase.
Calvert H; Azzariti A
Ann Oncol; 2011 Jan; 22 Suppl 1():i53-9. PubMed ID: 21285153
[TBL] [Abstract][Full Text] [Related]
5. [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
Kluzek K; Białkowska A; Koczorowska A; Zdzienicka MZ
Postepy Hig Med Dosw (Online); 2012 Jun; 66():372-84. PubMed ID: 22706123
[TBL] [Abstract][Full Text] [Related]
6. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
7. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.
McCabe N; Lord CJ; Tutt AN; Martin NM; Smith GC; Ashworth A
Cancer Biol Ther; 2005 Sep; 4(9):934-6. PubMed ID: 16251802
[TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.
Leung M; Rosen D; Fields S; Cesano A; Budman DR
Mol Med; 2011; 17(7-8):854-62. PubMed ID: 21424107
[TBL] [Abstract][Full Text] [Related]
10. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.
Lord CJ; Tutt AN; Ashworth A
Annu Rev Med; 2015; 66():455-70. PubMed ID: 25341009
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
[TBL] [Abstract][Full Text] [Related]
12. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Tutt A; Robson M; Garber JE; Domchek SM; Audeh MW; Weitzel JN; Friedlander M; Arun B; Loman N; Schmutzler RK; Wardley A; Mitchell G; Earl H; Wickens M; Carmichael J
Lancet; 2010 Jul; 376(9737):235-44. PubMed ID: 20609467
[TBL] [Abstract][Full Text] [Related]
13. [Hereditary breast and ovarian cancers].
Gevensleben H; Serçe N; Büttner R
Pathologe; 2010 Oct; 31(6):438-44. PubMed ID: 20848107
[TBL] [Abstract][Full Text] [Related]
14. [PARP inhibitors--theoretical basis and clinical application].
Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibitors stumble in breast cancer.
Guha M
Nat Biotechnol; 2011 May; 29(5):373-4. PubMed ID: 21552220
[No Abstract] [Full Text] [Related]
16. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
[TBL] [Abstract][Full Text] [Related]
17. Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
Plummer R
Breast Cancer Res; 2011 Aug; 13(4):218. PubMed ID: 21884642
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitors in the management of breast cancer: current data and future prospects.
Livraghi L; Garber JE
BMC Med; 2015 Aug; 13():188. PubMed ID: 26268938
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibitors and their evolving role in breast cancer.
Roop RP; Ma CX; Ellis MJ
Oncology (Williston Park); 2011 Oct; 25(11):1033-4. PubMed ID: 22106554
[No Abstract] [Full Text] [Related]
20. The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y; Calvert H
Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]